BOEHRINGER-INGELHEIM
14.9.2023 10:11:25 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi). This validation underlines the company’s commitment to aligning its efforts to tackle climate change and reduce global warming in line with the 2015 Paris Agreement. The SBTi drives ambitious climate action in the private sector, by enabling organizations to set science-based emissions reduction targets, while maximizing transparency, accountability, and corporate leadership through annual disclosure and progress against the targets.
“Driving environmental stewardship to decarbonize our business operations, both within and beyond the factory gates, has been a long-time priority at Boehringer Ingelheim,” said Felix Gutsche, Boehringer Ingelheim’s Head of Corporate Strategy & Consulting. “Having our emissions reduction targets approved by a respected organization like SBTi confirms that our efforts align with the current global agenda.”
In 2021 Boehringer Ingelheim committed reducing absolute scope 1 and 2 GHG emissions1 by 58.9 percent and absolute scope 3 GHG emissions2 by 27.5 percent (from a 2019 base year). The recent SBTi verification underscores Boehringer Ingelheim’s ongoing efforts.
The company recently added its production sites Fornovo (Italy) and Paulínia (Brazil) to its list of carbon-neutral certified sites, bringing the total to seven worldwide. This achievement resulted amongst others from the purchase and installation of renewable energy solutions, as well as ambitious carbon reduction measures. At other sites, including Dortmund and Katharinenhof (Germany), Gainesville (USA), Sant Cugat (Spain), and Zhangjian (China) the company initiated the integration of circular economy principles into development and manufacturing processes, green mobility concepts, as well as sustainability building standards, e.g., Leadership in Energy and Environmental Design (LEED) certification for office buildings.
Boehringer Ingelheim’s efforts to implement its low-carbon transformation are driven through the MORE GREEN pillar within its Sustainable Development - For Generations program. To foster low-carbon technologies and solutions, Boehringer Ingelheim applies an internal carbon price of EUR 100 per ton CO2 emissions for investments, which has been fully established at all sites. The company also emphasizes environmental sustainability in larger projects, providing another EUR 130 million for projects that contribute to the global MORE GREEN goals. This fund has now initiated over 60 new environmental sustainability projects since 2020.
To support certified climate contribution projects that help mitigate the environmental impact of currently unavoidable emissions, Boehringer Ingelheim continues to partner with ClimateSeed. This reputable social enterprise offers a broad portfolio of internationally recognized Verified Emissions Reduction projects that not only safeguard biodiversity and ecosystem services, but also benefit local communities.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/sustainable-development/more-green/boehringer-receives-sbti-validation-co2-reduction
References:
1Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.
2Scope 3 GHG emissions are emissions from purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution and use of sold products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914610507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
